What is CAR T-cell therapy?

CAR T-cell therapy is a type of cancer therapy that uses a patient’s own modified white blood cells to kill cancer cells.

What types of cancer does CAR T-cell therapy treat?

Two CAR T cell therapies are currently available – axicabtagene ciloleucel (Yescarta®) and tisagenlecleucel (Kymriah®).

Yescarta® has been approved by the Food and Drug Administration (FDA) to treat adults with large B-cell non-Hodgkin lymphomas (including diffuse large B-cell lymphoma –DLBCL) whose cancer has returned or has not been fully successfully treated with at least two prior treatment regimens. Lymphoma is a cancer of the body’s immune system. Kymriah® is approved for children and adults up to age 25 with advanced acute lymphoblastic leukemia (cancer of the body’s blood-forming tissues).

Other CAR T-cell therapies are being developed for other blood cancers including chronic lymphocytic leukemia, other forms of lymphoma, and multiple myeloma.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy